HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Ductal carcinoma is a type of breast cancer that originates in the milk ducts, which are the passages that carry milk from the lobules to the nipple during breastfeeding. This form of cancer is the most common type of breast cancer, accounting for about 80% of all cases. Ductal carcinoma can present in two main subtypes: ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC). DCIS is confined to the ducts and has not invaded surrounding tissues, while IDC has penetrated nearby tissues and may potentially spread to other parts of the body. The exact cause of ductal carcinoma is not fully understood, but certain risk factors, such as age, gender, family history, and hormonal factors, may increase the likelihood of its development. Regular mammograms and self-examinations are crucial for early detection, as early-stage ductal carcinoma is often more treatable and has a better prognosis. Treatment options for ductal carcinoma depend on various factors, including the stage of the cancer, its molecular characteristics, and the overall health of the patient. Common treatment approaches include surgery, chemotherapy, radiation therapy, hormone therapy, and targeted therapy. A multidisciplinary approach involving oncologists, surgeons, and other healthcare professionals is often employed to tailor the treatment plan to the individual needs of the patient. It is important for individuals to be aware of potential symptoms, such as changes in breast appearance or the presence of lumps, and to promptly seek medical attention if any abnormalities are detected. Advances in research and medical technology continue to enhance our understanding of ductal carcinoma and improve treatment outcomes for those affected by this prevalent form of breast cancer. Regular screenings, early detection, and comprehensive treatment strategies play crucial roles in managing and combating ductal carcinoma.
